[go: up one dir, main page]

MX2018006266A - Formulaciones de benzofuranos 2-heteroaril-sustituidos. - Google Patents

Formulaciones de benzofuranos 2-heteroaril-sustituidos.

Info

Publication number
MX2018006266A
MX2018006266A MX2018006266A MX2018006266A MX2018006266A MX 2018006266 A MX2018006266 A MX 2018006266A MX 2018006266 A MX2018006266 A MX 2018006266A MX 2018006266 A MX2018006266 A MX 2018006266A MX 2018006266 A MX2018006266 A MX 2018006266A
Authority
MX
Mexico
Prior art keywords
heteroaryl substituted
formulations
substituted benzofurans
benzofuran derivatives
substituted benzofuran
Prior art date
Application number
MX2018006266A
Other languages
English (en)
Inventor
R Cesati Richard Iii
S Casebier David
Christian MORETON Richard
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of MX2018006266A publication Critical patent/MX2018006266A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen procesos y composiciones para derivados de benzofurano sustituido con 2-heteroarilo. los derivados de benzofurano sustituido con 2-heteroarilo pueden ser adecuados para preparar derivados de benzofurano 2-heteroaril-sustituidos radio-marcados para formar imágenes de depósitos amiloides en pacientes vivos.
MX2018006266A 2015-11-20 2016-11-21 Formulaciones de benzofuranos 2-heteroaril-sustituidos. MX2018006266A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258309P 2015-11-20 2015-11-20
US201562258326P 2015-11-20 2015-11-20
PCT/US2016/063154 WO2017087965A1 (en) 2015-11-20 2016-11-21 Formulations for 2-heteroaryl substituted benzofurans

Publications (1)

Publication Number Publication Date
MX2018006266A true MX2018006266A (es) 2019-05-06

Family

ID=58717976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006266A MX2018006266A (es) 2015-11-20 2016-11-21 Formulaciones de benzofuranos 2-heteroaril-sustituidos.

Country Status (8)

Country Link
US (1) US20180344881A1 (es)
EP (1) EP3377058A4 (es)
JP (1) JP2018534334A (es)
KR (1) KR20180113975A (es)
AU (1) AU2016355723A1 (es)
CA (1) CA3006054A1 (es)
MX (1) MX2018006266A (es)
WO (1) WO2017087965A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
CA2877516A1 (en) * 2012-07-03 2014-01-03 Janssen Alzheimer Immunotherapy C-terminal and central epitope a-beta antibodies
CA2922559A1 (en) * 2013-08-27 2015-03-05 Crc For Mental Health Ltd Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases

Also Published As

Publication number Publication date
US20180344881A1 (en) 2018-12-06
WO2017087965A1 (en) 2017-05-26
JP2018534334A (ja) 2018-11-22
CA3006054A1 (en) 2017-05-26
AU2016355723A1 (en) 2018-06-21
EP3377058A1 (en) 2018-09-26
EP3377058A4 (en) 2019-08-14
KR20180113975A (ko) 2018-10-17

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
PT3378859T (pt) Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina
PL3402480T4 (pl) Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu
EP3397200A4 (en) KNEE PROSTHESIS IMPLANT
MA39479A (fr) Structure prosthetique d'implant dentaire
GB201714274D0 (en) Paleogeographic reconstruction of an area of the earth crust
ZA201806418B (en) Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
IL255178B (en) Strigolactones or their derivatives for use in increasing the yield of a cultivated plant
WO2016094374A8 (en) Compositions and methods for treatment of friedreich's ataxia
EP3531898A4 (en) IMPLANT FOR BONE RECONSTRUCTION
PL3377909T3 (pl) Laktoferyna do zastosowania w diagnozowaniu lub prognozowaniu choroby Alzheimera
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
IL257787B (en) A consumable medical device for breast reconstruction or augmentation
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
EP3355833A4 (en) hip prosthesis
PT3283064T (pt) Derivados úteis para o tratamento da atrofia muscular
EP3247802A4 (en) Protease-activated contrast agents for in vivo imaging
IT201700037319A1 (it) Composizione naturale per uso in ginecologia
PL3582796T3 (pl) Kompozycja do leczenia kaszlu
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
SI3381457T1 (sl) Fiziološka aktivna sestava, ki vsebuje N-acetilglukozamin za zdravljenje bolečin v hrbtu
BR112017014842A2 (pt) composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem
SG10201606557RA (en) Oxygen-enriched water composition, biocompatible composition comprising the same, and methods of preparing and using the same
MX2018006266A (es) Formulaciones de benzofuranos 2-heteroaril-sustituidos.
PL3442397T3 (pl) Dwuczęstotliwościowe badanie stomatologiczne